You are here

Saracatinib Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition

The FDA has awarded orphan drug status to AstraZeneca’s AZD0530 (Saracatinib), a potential new drug for the treatment of idiopathic pulmonary fibrosis (IPF).

IPF, a chronic, progressive, irreversible, and typically fatal interstitial lung disease, affects approximately 100,000 people in the U.S. Patients with IPF generally live between two and five years from diagnosis, as there are few medicines available for treating the disease. 

Pre-clinical trials of AZD0530 showed that it inhibits fibroblast activity and collagen deposition, which are key features of lung fibrosis.

AZD0530 is a small molecule, highly potent, selective inhibitor of src tyrosine kinase, which regulates broad cell functions including cell growth and cell differentiation. Phase 2 trials for AZD0530 in IPF have not yet commenced.

Source: AstraZeneca, March 18, 2019

Recent Headlines

Company says it is offering a more affordable generic to the agent used to treat varicose veins
Company, FDA held a meeting to discuss trials in bunion, "tummy tuck" patients
New model uses piezoelectric material used in microphones and high-end speakers
Rozanolixizumab touted as possible alternative to standard therapy of corticosteroids, intravenous immunoglobulin
Heart rate variability may pinpoint who will benefit
Researchers found that ECMO before transplant tripled chance of a long hospital stay
18 of 25 were 'iron replete' after a single infusion
Intrauterine environment may have a 'programming effect' on fetal heart